💉 Congenital Rubella Syndrome Prevention Simulator

An Unvaccinated Woman Carries No Rubella Defense

Without MMR vaccination, a woman has zero rubella-specific antibodies.

• 2: MMR doses needed (for full immunity)
• ~97%: Seroconversion rate (after 2 doses)
• ~5–10%: Natural immunity gap (of unvaccinated adults)
• Lifelong: Antibody persistence (after full series)

Susceptibility without vaccination

No prior MMR dose leaves no neutralizing IgG in maternal blood.

Any rubella exposure can establish infection unopposed.

Pre-pregnancy screening catches this gap before conception.

Why timing before pregnancy matters

MMR is a live vaccine, unsafe to give during pregnancy itself.

Immunity must be built beforehand, then confirmed by titer.

Women should wait ~1 month after MMR before conceiving.

Global susceptibility gaps persist

Many countries lack universal childhood MMR coverage.

Adult women who missed doses remain silently vulnerable.

Outbreaks still occur where coverage dips below ~95%.

Rubella-susceptible women of childbearing age remain the single largest driver of congenital rubella syndrome worldwide.

First-Trimester Rubella Is the Highest-Risk Window

Infection in early pregnancy carries the greatest fetal danger.

• ~85%: Defect risk, weeks 1–12 (if infected)
• ~35%: Defect risk, weeks 13–16 (declining sharply)
• ~1–2%: Defect risk, after week 20 (rarely affected)
• Mild: Maternal symptoms (often unnoticed)

Why the first trimester is critical

Fetal organs are actively forming in weeks 1–12.

Viral disruption during organogenesis causes lasting malformation.

Later exposure meets already-formed, more resilient tissue.

A deceptively mild maternal illness

Rubella in adults often causes only rash and low fever.

Mothers may not realize they were ever infected.

Subclinical infection still endangers the fetus equally.

Viremia precedes fetal risk

Virus circulates in maternal blood before symptoms appear.

This viremic window is when placental exposure begins.

Early detection rarely arrives in time to intervene.

Risk falls from roughly 85% in month one to under 2% after twenty weeks — timing decides nearly everything.

Rubella Virus Crosses the Placental Barrier

The placenta cannot always stop rubella from reaching the fetus.

• ~80%: Placental transmission rate (first trimester)
• Togavirus: Virus type (RNA, enveloped)
• Syncytiotrophoblast: Barrier layer (villi surface)
• Days: Fetal infection onset (after maternal viremia)

How the virus breaches the villi

Rubella infects placental syncytiotrophoblast cells directly.

From there it spreads into fetal capillaries within the villi.

No maternal antibody means no interception along the way.

Chronic, persistent fetal infection

Unlike many viruses, rubella persists for months in fetal tissue.

Infected cells divide more slowly, stunting organ growth.

This chronic damage compounds across every trimester it continues.

Antibodies as the only real checkpoint

Maternal IgG, when present, neutralizes virus before placental entry.

Without it, the placenta offers little independent protection.

The barrier is porous to rubella, not a true wall.

The placenta is not a fortress against rubella — maternal antibody, not anatomy, is the real checkpoint.

Congenital Defects: Deafness, Cataracts, Heart, Delay

Fetal rubella infection produces a recognizable defect triad.

• ~60%: Sensorineural deafness (of CRS cases)
• ~25%: Cataracts / eye defects (of CRS cases)
• ~50%: Congenital heart defects (PDA most common)
• Common: Developmental delay (varies by severity)

The classic CRS triad

Deafness, cataracts, and heart defects define classic CRS.

Any combination can appear depending on infection timing.

Earlier infection tends to produce more severe, multi-organ disease.

Beyond the triad

Microcephaly, growth delay, and liver or spleen enlargement occur.

Developmental delay often emerges only in later childhood.

Some infants shed live virus for over a year.

A single infection, lifelong consequences

CRS damage is permanent — organs cannot regenerate lost function.

Management is lifelong: hearing aids, surgery, therapy, monitoring.

Every case traces back to one preventable maternal exposure.

A single unprevented infection can cause deafness, blindness, heart disease, and lifelong delay all at once.

MMR Vaccination Blocks the Entire Cascade

One vaccination step upstream prevents every downstream harm.

• ~97%: MMR effectiveness (against rubella)
• ~0: CRS cases if immune (per pregnancy)
• ≥1 month: Pre-conception window (before pregnancy)
• Achievable: Global CRS elimination (via coverage)

Antibodies stop the virus at the door

Vaccine-induced IgG neutralizes rubella before it reaches the placenta.

No maternal viremia means no placental exposure at all.

The fetus is shielded without ever facing the virus.

One dose, whole-pathway prevention

Blocking stage one erases every later stage automatically.

No infection, no crossing, no defects — one clean break.

This is why pre-pregnancy screening is so cost-effective.

Population immunity protects everyone

High MMR coverage reduces circulating rubella community-wide.

Fewer outbreaks mean fewer exposure opportunities altogether.

Several regions have already eliminated endemic rubella entirely.

Congenital rubella syndrome is one of the most completely preventable causes of birth defects known to medicine.